SAC Loses Almost $200M On Drug Co.

Aug 5 2011 | 12:39pm ET

Paulson & Co. isn't the only big hedge fund nursing a nine-figure loss this summer.

When pharmaceutical company Dendreon Corp. withdrew its 2011 revenue estimate after it admitted it was still struggling to educate doctors about its new prostate-cancer drug, Provenge. That sent the company's shares down by two-thirds, and left SAC Capital Advisors with a paper loss of $196 million.

SAC's prostate problems follow Paulson's $574 million loss on Chinese timber company Sino-Forest last month. Sino-Forest shares plummeted by some 90% in the wake of a research report accusing the company of overstating its timberland holdings.

SAC is Dendreon's biggest shareholder, but not its only shareholder among hedge funds. Balyasny Asset Management, Citadel Investment Group, Healthcor Management, Millennium Management, Soros Fund Management and Visium Asset Management all owned sizeable stakes in the company, as well.


In Depth

Fundraising for Mid-Sized PE Funds: Should You Use a Registered B/D?

Dec 6 2016 | 7:18pm ET

When does a fund sponsor need to use a registered broker/dealer when raising capital...

Lifestyle

Trump Attends 'Villains and Heroes' Costume Party Dressed As...Himself

Dec 5 2016 | 11:16pm ET

U.S. President-elect Donald Trump attended a "Villains and Heroes" costume party...

Guest Contributor

A Hard Look At Your ‘Soft’ Hedge Fund Marketing Information

Dec 8 2016 | 9:03pm ET

Conventional wisdom holds that due diligence examines quantitative as well as qualitative...

 

From the current issue of

Since the inception of Modern Trader, a core editorial theme has centered on the wisdom and power of crowds. Editorial emphasis has focused on companies and projects engaged in the collection and analysis of information. 

AVAILABLE NOW at BARNES & NOBLE

NEWSTAND LOCATOR